Hormonal Contraception Research Articles

HUBUNGAN PERAN BIDAN DAN DUKUNGAN SUAMI TERHADAP PENGGUNAAN IUD DI WILAYAH KERJA PUSKESMAS SRANDAKAN

Indonesia prioritizes the Family Planning (KB) program, especially Long Term Contraceptive Methods (MKJP) such as the Intrauterine Device (IUD). The use of IUDs in DI Yogyakarta is more popular even though injectable hormonal contraceptives are still dominant in Indonesia, the Srandakan Community Health Center in Bantul recorded the highest use of IUDs (44.5%). National development targets in the strategic plan and target setting for the 2020-2024 BKKBN program, as well as international agreements in the SDGs development goals to increase participation rates in the use of MKJP, this makes it an important issue for participation in the use of MKJP, especially the IUD, which is a contraceptive device that is considered effective. The availability of information and social support from midwives and husbands is key in increasing the acceptance and continued use of IUD contraception by WUS. This study aims to determine the relationship between the role of midwives and husband's support on the use of IUDs by WUS in the Srandakan Community Health Center Work Area, Bantul Yogyakarta. This research is a quantitative study with a correlational analytical design and a cross-sectional approach. The sampling technique used accidental sampling with a total population of 1,034 WUS and a sample of 92 respondents. The research instrument used a questionnaire. The research results were obtained from the Fisher's Exact Test which showed a significant relationship between the role of the midwife (p=0.019) and husband's support (p= <0.001) on IUD use. Based on these results, it can be concluded that the role of the midwife and the husband's support influence the decision to use IUD contraception.

Factors Associated with Discontinuation of Using Hormonal Contraceptive Methods in Alexandria Governorate.

Factors Associated with Discontinuation of Using Hormonal Contraceptive Methods in Alexandria Governorate.

The male birth control pill - A new approach to family planning and population control.

With the increase in the world's population, contraception is crucial in population control strategies. Majority of contraceptives produced today are targeted at women; many of whom experience side effects, leading to the discontinuation of these contraceptives after a year of use. As the use of condoms and vasectomies has been subjected to scrutiny, it is necessary for the development of male birth control (BC). Attempts to achieve this include hormonal and non-hormonal contraception. Hormonal contraception prevents the production of the sperm in the testes; but this mode of BC has been found to be ineffective while also causing behavioural changes in men. In contrast, non-hormonal male contraception focuses on rendering the sperm immotile to prevent fertilization post-copulation. Soluble adenylate cyclase is an area of research that has shown promise in this field. Furthermore, two inhibitors, TDI-10299 and TDI-11861, have been developed and tested, with the latter, showing greater potency and longer activity, in mice models. Overall, by developing non-hormonal male contraceptives, men will have more control over their reproductive health. Nonetheless, before such contraceptives can be made widely available, it is important that further research takes place to ensure the safety and effectiveness of these methods.

Diagnosis and treatment of venous thrombosis - part 2

The subject of this guideline from the Institute of Family Medicine at the University of Zurich (IHAMZ) is the management of venous thrombosis. The review summarizes the current evidence and recommendations from international guidelines (1-6). The IHAMZ-guidelines focus on primary care, they also provide guidance on the coordination of general and specialist medical care as well as on the transition between outpatient and hospital care taking into account the special features of the Swiss healthcare system. The guideline is devided in two parts. Part 1 discusses the diagnosis and treatment of deep vein thrombosis (DVT). A validated algorithm is recommended for the diagnostic process, which begins with the assessment of the clinical probability. With the inclusion of the D-dimer test, the need for subsequent imaging diagnostics can be reduced. The differences between the evaluation of an initial and recurrent DVT are shown and the indications and scope of evidence-based environmental diagnostics (thrombophilia and tumor search) are presented. All patients with DVT should receive anticoagulation (AC) for 3-6 months, as there is a high risk of recurrence with AC 3 months. The duration of the subsequent secondary prophylaxis depends on the presumed risk of recurrence on the one hand and the risk of bleeding on the other. Part 2 is dedicated to special thrombosis situations such as isolated distal thrombosis of the deep and muscle veins (idDVT, iMVT), shoulder-arm vein thrombosis (SAVT), cancer-associated thrombosis (CAT) and superficial vein thrombosis (SVT). The article on hormone- and pregnancy-associated DVT, developed together with the Department of Gynecology at the University Hospital of Zurich, discusses the importance of hormonal contraception and menopausal hormone replacement therapy (HRT) as thrombogenic risk factor as well as special features in the diagnosis and treatment of thrombosis in pregnancy.

Population differences in responses to male hormonal contraception (lessons learned from the WHO-CONRAD phase III study)

Population differences in responses to male hormonal contraception (lessons learned from the WHO-CONRAD phase III study)

Population differences in responses to male hormonal contraception (lessons learned from the WHO-CONRAD phase III study)

Population differences in responses to male hormonal contraception (lessons learned from the WHO-CONRAD phase III study)

P10-22 Analysing women's knowledge in hormonal contraception for reproductive health: insights from a Romanian study

P10-22 Analysing women's knowledge in hormonal contraception for reproductive health: insights from a Romanian study

Hormonal contraceptive use, not menstrual cycle phase, is associated with reduced interest in competition

Despite numerous studies attempting to understand the influence of fertility and hormonal contraceptives on competitive outcomes, the association between these variables remain a contentious issue. Using a longitudinal, online diary study with over 5600 daily observations (N = 302 community and undergraduate student participants), we explored the effects of fertility probability and hormonal contraceptive use on a range of self-report competitive outcomes. Specifically, we sought to replicate existing findings by examining whether self-reported competitive motivation increases mid-cycle and how hormonal contraceptive use affects these patterns. We also sought to extend this literature by collecting a range of self-report measures of competitive behavior across the menstrual cycle. Using an evolutionary and data-driven framework, we combined six behaviors females use to compete for mates and status: gossip, social comparison, negative evaluations of others, appearance enhancement, giving advice and taking sexy self-portraits. Contrary to our predictions, fertility probability was not associated with fluctuations in self-reported competitive motivation or behavior. However, replicating existing literature, hormonal contraceptive users reported a general lack of interest in competition compared to non-users. This latter finding raises important questions about the long-term implications of hormonal contraceptive use and suggests a need for further research to investigate the psychosocial effects of hormonal contraceptives. Finally, as a near direct replication of an existing longitudinal study, the current research offers a unique contribution by considering the role of context in hormone mediated research. We question the idea that a failure to replicate reflects the quality of the theory or the research, but instead suggest that context should be considered when developing psychological theory.

Risk factors of pyometra in cat at several clinics in Kediri, East Java, Indonesia

Pyometra is a reproductive disease that most often affects cats which is caused by bacterial infection of the uterus. This study aims to determine the risk factors that could influence the occurrence of pyometra in cats. The study was conducted at the Four Leg Pet Care, Asa Animal Clinic, and K-5 Animal Care in Kediri regency in December 2021 to February 2022. This retrospective cohort study took secondary data for the period 2020 to 2021 as research material and found 35 cats diagnosed with pyometra. The odds ratio was calculated to analyze the associations to some factors including age, body weight, use of hormonal contraception, frequency of administration of hormonal contraception, hormonal contraceptive drugs used, dose of hormonal contraception given. Analysis of the relationship between risk factors for pyometra showed that the factors age, use of hormonal contraception, and frequency of giving hormonal contraceptives each have p values ​​of 2.17, 2.13, and 2.13, respectively. It could be concluded that age, use of hormonal contraception, and frequency of administration of hormonal contraception influenced or had an association with the risk of pyometra in cats.

Factors influence the severity of premenopause syndrome

Background: Premenopause syndrome triggers more severe physical and psychological problems and the emergence of various diseases. The limited research on the factors causing the severity of Premenopause syndrome has resulted in a lack of efforts to address the causative factors. Purpose: This study aims to explore factors that influence the severity of premenopause syndrome.Method: This is an analytic observational study with a cross-sectional design. Eighty-eight women aged 40-45 years were included in this study. The knowledge, attitude, age of menarche, use of hormonal contraceptives, and symptoms of premenopause syndrome observed in this study—data analysis using chi-square and multiple logistic regression.Results: Factors that influence the severity of premenopause syndrome are knowledge, attitude, age of menarche, and use of hormonal contraceptives (p<0.001). Knowledge is the most dominant factor (Exp(B) = 25.983; p<0.05)Conclusion: These results underscore the importance of increasing the knowledge of premenopause women to reduce the severity.

Emotion and birth control: Emotion regulation ERPs differ based on menstrual cycle phase and hormonal contraceptive use

While hormonal contraceptives (HCs) like oral contraceptive pills (OCs) and intrauterine devices (IUDs) can reportedly influence mood, the evidence is mixed, and the mechanisms remain unclear. Emotion reactivity and regulation processes may be hormone-sensitive and underlie these mood changes. This study sought to investigate the role of the menstrual cycle and HC use in emotion regulation using ERP measures during an emotion regulation paradigm. Participants with a natural cycle (NC) were measured in the mid-follicular and mid-luteal phase (within-subject design, n = 26), and compared with OC (n = 36) and IUD (n = 25) users. The centroparietal late positive potential (LPP) reflected negative emotion reactivity and its modulation by cognitive reappraisal served as a marker for emotion regulation processing. NC participants had a lower LPP amplitude in the mid-luteal compared to the mid-follicular phase. Reactivity to negative emotional stimuli decreased over time in the mid-luteal phase, whereas the HC groups showed sustained LPP activation. Reappraisal led only to significant LPP changes in the mid-follicular phase, and not in the mid-luteal phase or HC groups. Our results showed a specific left frontal activity (FR-LPP) in the contrast that reflected emotion regulation processing. This activity was highest in the mid-follicular phase, and was significantly different from the OC users but not from the IUD group. Higher self-reported PMS symptoms were associated with stronger effects on the reduced mid-luteal LPP activity and with lower FR-LPP amplitude in the mid-follicular phase. No effect of OC phase (active pill use versus pill pause) was found. These findings add insights into the neurophysiological underpinnings of hormone-related mood changes and demonstrate the importance of considering hormonal status and PMS symptoms in emotion research.

ПРИОРИТЕТЫ ВЫБОРА СРЕДСТВ КОНТРАЦЕПЦИИ СТУДЕНТКАМИ МЕДИЦИНСКОГО УНИВЕРСИТЕТА

Purpose: To determine the priorities of contraceptive choices of medical students depending on various factors. Materials and methods: 75 female students of North-Western State Medical University named after I.I. Mechnikov participated in the study; mean age was 20,5 years, 77% were sexually active. Information was collected using a specially designed questionnaire that included questions about the characteristics of sexual life (duration, number of partners, frequency of partner changes, regularity of sex), methods of contraception and the reasons for their choice, diagnosis and prevention of STIs, the effect of contraception on the menstrual cycle and its characteristics, and sexual life. Pearson criterion at p≤0.05 was applied in data analysis. Female Sexuality Index (FSI) was assessed using The Female Sexual Function Index (FSFI) questionnaire. Results: the predominant method of contraception choice among the respondents depending on sexual experience was the barrier method. With increasing sexual experience, the proportion of girls using interrupted intercourse increased and the proportion using hormonal contraception decreased. The predominant contraceptive method among girls who rarely change sexual partners was the condom, while girls with frequent changes in sexual partners preferred to use the standard day method. The reasons for choosing a contraceptive method were the fear of unwanted pregnancy, simplicity and ease of use of the method, and the lack of impact on sexual pleasure. The vast majority of all respondents were primarily afraid of HIV infection, syphilis, and the development of acquired immunodeficiency syndrome (AIDS). Girls using hormonal contraception were primarily guided by a doctor's prescription when choosing a method. The majority in this group had a positive effect of the method on the menstrual cycle and a decrease in pain in the mammary glands was observed with the start of contraception. The maximum index of female sexuality was found in the groups of girls using spermicides and the standard days method, and the lowest - in female students not using contraception. Conclusion: barrier and natural methods of contraception were the priority of choice for most of the respondents.

Age and Menopausal Status in Idiopathic Subglottic Stenosis.

To evaluate the impact of age on disease recurrence in idiopathic subglottic stenosis (iSGS) patients. This was a retrospective chart review of iSGS patients treated with laser wedge excision. Patients did not have prior surgery. Survival rates free of recurrence were estimated using the Kaplan-Meier methods, and associations were evaluated using Cox Proportional Hazards models. Eighty-five female patients were included in the study. Most patients (68%) were postmenopausal, had first period at or before 13 years of age, had at least one full-term pregnancy (82%), were not undergoing hormone replacement therapy (93%), were not using hormonal birth control (88%), and were either partially or completely compliant with triple therapy regime (80%). There was a statistically significant average reduction in risk of recurrence of 5% for every additional year of age (p < 0.0001). When compared to patients older than 65 years of age, patients less than 35 were nearly 10 times more likely to recur (p = 0.002), and patients 55-65 and 45-55 years of age were 8 and 5 times more likely to recur, respectively (p = 0.003 and 0.009). Additionally, females on birth control showed decreased risk of recurrence of 74% compared with their counterparts (p = 0.04). This is the first study to demonstrate an inverse relationship between age and disease recurrence in patients with iSGS following surgery. Using age as a surrogate for menopausal status, these results suggest that increased age and/or birth control provide a protective effect through decreased recurrence rates, possibly mediated by decreased estrogen levels. 4 Laryngoscope, 2024.

Effects of Hormonal Contraception and the Menstrual Cycle on Maximal Strength and Power Performance.

To evaluate the effects of oral contraceptive (OC) and hormonal intrauterine device (H-IUD) use, compared to an eumenorrheic (EUM) cycle, on maximal strength and power between hormone phases. One repetition max (1RM) leg press and bench press, peak force (PF) from knee extension and upright row isometric dynamometry, and power from vertical jump height (VJH) and reactive strength index (RSI; cm/s) were measured in 60 healthy, active women (mean ± standard deviation [SD]; Age: 26.5 ± 7.0 yrs, BMI: 22.5 ± 3.7 kg/m2) who were monophasic OC users for ≥6 months (n = 21), had a H-IUD for ≥6 months (n = 20), or had regularly naturally occurring menstrual cycle for ≥3 months or were using a non-hormonal IUD (EUM; n = 19). Participants were randomly assigned to begin in the follicular phase/placebo pill (low hormone phase; LHP) or in the luteal phase/active pill (high hormone phase; HHP) and were tested once in each phase. Estimates of total lean mass (LM), leg LM, and arm LM were measured via dual energy x-ray absorptiometry. Separate univariate ANCOVAs were used to assess the change from HHP to LHP between groups, with LM and progesterone as covariates. Leg press 1RM was significantly different across phases between groups (p = 0.027), with higher leg press 1RM in the HHP for the OC group (mean difference[∆HHP-LHP] ± standard error: ∆7.4 ± 15.9 kg; p = 0.043) compared to the H-IUD group (∆-8.9 ± 23.8 kg; p = 0.043). All groups demonstrated similar bench press 1RM, PF, VJH, and RSI between phases (p > 0.05). Lower body strength was greater in the HHP for OC users (5.6% increase) suggesting lower body maximal strength outcomes may be influenced by hormonal contraception type.

Testosterone and male contraception.

Rates of unintended pregnancy have remained relatively stagnant for many years, despite a broad array of female contraceptive options. Recent restrictions on access to abortion in some countries have increased the urgency for expanding contraceptive options. Increasing data suggest men are keen to utilize novel reversible male contraceptives. Despite decades of clinical research in male contraception, no reversible hormonal product currently exists. Nestorone/testosterone, among other novel androgens, shows promise to finally move to pivotal Phase 3 studies and introduction to the marketplace. Hormonal male contraception utilizes androgens or androgen-progestin combinations to exploit negative feedback that regulates the hypothalamic-pituitary-testicular axis. By suppressing release of gonadotropins, these agents markedly decrease endogenous testosterone production, lower intratesticular testosterone and suppress spermatogenesis. The addition of a progestin enhances the degree and speed of sperm suppression. The androgen component preserves a state of symptomatic eugonadism in the male. There is growing demand and acceptance of male contraceptive options in various forms. As these formulations progress through stages of drug development, regulatory oversight and communication with developers around safety and efficacy standards and garnering industry support for advancing the production of male contraceptives will be imperative.

The impact of mental health and psychological stressors on menstrual cycle modulation: exploring the influence of age and hormonal contraceptives.

The objective of this study was to analyze the influence of a stressor, a period of the Covid-19 pandemic when there were no vaccines available yet, on the psychological state of women aged 18 to 45 years; as well as the influence of mental health on the menstrual cycle, considering the influence of age and hormonal contraceptives. Online questionnaire using the Google Forms platform was used. There is a high prevalence of the onset of new psychosocial symptoms. Moreover, most women reported some type of change in their menstrual cycles. The women who were using hormonal contraceptives demonstrated a higher frequency of spotting and menstrual color alterations, while women without hormonal contraceptives demonstrated a higher frequency of cycle duration and menstrual odor alterations. Women without hormonal contraceptives were more susceptible to the development of psychosocial symptoms. Younger adult women were more affected by menstrual changes and psychosocial symptoms. Close to 90% of women who reported several psychosocial symptoms had changes in their menstrual cycles. These data suggest the impact of stressors, such as a period of the pandemic, on mental health and menstrual cycles, and younger adult women can be more susceptible. This reflects the relationship between mental and reproductive health.

Twelve-Month Contraceptive Supply Policies and Medicaid Contraceptive Dispensing

Nineteen states have passed legislation requiring insurers to cover the dispensation of a 12-month supply of short-acting, hormonal contraception. To determine whether 12-month contraceptive supply policies were associated with an increase in the receipt of 12-month or longer supply of contraception. This retrospective cohort study included data from all female Medicaid enrollees aged 18 to 44 years who used short-acting hormonal contraception (ie, pill, patch, or ring) from 2016 to 2020. Eleven treatment states where legislation required insurers to cover a 12-month supply of contraception to continuing users and 25 comparison states without such legislation prior to December 2020. Proportion of contraception months received via a single 12-month or longer fill. This study included 48 255 512 months of dispensed oral pill, patch, and ring contraception prescription supply among 4 778 264 female Medicaid enrollees. The majority of months of supplied contraception were for the contraceptive pill rather than the patch or ring. In a staggered difference-in-differences model, the 12-month supply policy was associated with an estimated 4.39-percentage point (pp) increase (95% CI, 4.38 pp-4.40 pp) in the proportion of contraception dispensed as part of a 12-month or longer supply, from a mean of 0.11% in treatment states during the first quarter of the study period. Investigating the heterogeneity in policy association across states, California stood out with a 7.17-pp increase (95% CI, 7.15 pp-7.19 pp) in the proportion of contraception dispensed as a 12-month or longer supply; in the other 10 treatment states, the policy association was less than 1 pp. In this cohort study of Medicaid recipients using short-acting hormonal contraception, the passage of a 12-month contraceptive supply policy was associated with a minimal increase in the proportion of contraception dispensed through a 12-month or longer supply.

Regulatory challenges of new male contraceptive methods.

Progress in male contraception development faces the challenge of a lack of regulatory precedent and guidelines on the evidence (trial design and primary endpoint) required for marketing approval. Moreover, the development of a male contraceptive is complicated by the fact that the clinical treatment effect; prevention of pregnancy, is not measured in the patient receiving the intervention. Regulatory precedent and guidelines exist for female hormonal contraceptives but their applicability to male contraceptive products likely varies based on the mode of action and the anticipated pharmacodynamic effects of the product. The unique attributes of male contraceptives, including the frequent delay between the intervention (e.g., vasectomy and hormonal methods) and ultimate contraceptive effect, sperm suppression near azoospermia, and pregnancy prevention need to be addressed. This article describes the regulatory challenges faced by developers of male contraceptive products and offers proposals, paving the way for the development of both hormonal methods and non-hormonal approaches. Our article intends to suggest the directions but cannot substitute for the advice of regulatory agencies.

Sexual function, quality of life, anxiety, and depression in women of reproductive age using hormonal, nonhormonal, and no contraceptive methods.

Hormonal contraceptive use has been related to adverse effects, including impacts on sexual function and sexual satisfaction, although the difference in the effects on sexual function with the use of hormonal vs nonhormonal contraceptive methods remains controversial. In this study we sought to compare the prevalence of dyspareunia, sexual function, sexual satisfaction, quality of life, anxiety, and depression between women using hormonal, nonhormonal, or no contraceptive methods and to compare these outcomes between the most frequently used contraceptive methods. This cross-sectional study included sexually active women of reproductive age who were stratified into 3 groups: women using hormonal, nonhormonal, or no contraceptive methods. Based on the use of questionnaires administered to the study participants, we compared sexual function in the 3 groups and more specifically among users of oral contraceptives, copper and hormonal intrauterine devices, and barrier methods. Participants completed 4 questionnaires to assess sexual function (Female Sexual Function Index), sexual satisfaction (Sexual Quotient-Feminine Version), quality of life (12-item Medical Outcomes Short Form Health Survey), and anxiety and depression (Hospital Anxiety and Depression Scale). This study included 315 women classified into 3 groups on the basis of contraceptive use: 161 in the hormonal contraceptives group (median [interquartile range] age, 24 [23-28] years), 97 in the nonhormonal contraceptives group (age 26 [23-30] years), and 57 in the no contraceptive methods group (age 28 [24-35] years). Dyspareunia prevalence showed no difference between the groups. In the quality of life domain, compared with women in the nonhormonal contraceptive group, women in the hormonal contraceptive group were younger and had lower sexual function satisfaction, reduced arousal, and heightened pain (P< .05), as well as higher anxiety and depression levels (P= .03, for both), increased pain (P= .01), and poorer overall health (P= .01). No difference was found between these groups in other quality of life domains. Regarding contraceptive methods, women using copper intrauterine devices had better sexual function, including higher rates of arousal and lower anxiety, than women using oral contraceptives (P< .05). The results of this study highlight worse sexual function and sexual satisfaction and higher levels of anxiety and depression in women using hormonal contraceptive methods than in women using nonhormonal methods. The findings of this study strengthen the evidence of differences in sexual function between women using oral contraceptives and those using copper intrauterine devices. Sexual function was also compared among users of oral contraceptives, copper and hormonal intrauterine devices, and barrier methods. However, less frequently used contraceptive methods, such as hormonal injections and vaginal rings, could not be compared in this sample. Women using hormonal contraceptive methods were younger, had lower sexual function and satisfaction, and experienced higher anxiety and depression levels than women using nonhormonal contraceptive methods.

Minimal influence of the menstrual cycle or hormonal contraceptives on performance in female rugby league athletes.

We examined performance across one menstrual cycle (MC) and 3weeks of hormonal contraceptives (HC) use to identify whether known fluctuations in estrogen and progesterone/progestin are associated with functional performance changes. National Rugby League Indigenous Women's Academy athletes [n=11 naturally menstruating (NM), n=13 using HC] completed performance tests [countermovement jump (CMJ), squat jump (SJ), isometric mid-thigh pull, 20m sprint, power pass and Stroop test] during three phases of a MC or three weeks of HC usage, confirmed through ovulation tests alongside serum estrogen and progesterone concentrations. MC phase or HC use did not influence jump height, peak force, sprint time, distance thrown or Stroop effect. However, there were small variations in kinetic and kinematic CMJ/SJ outputs. NM athletes produced greater mean concentric power in MC phase four than one [+0.41W·kg-1 (+16.8%), p=0.021] during the CMJ, alongside greater impulse at 50ms at phase one than four [+1.7N·s (+4.7%), p=0.031] during the SJ, without differences between tests for HC users. Among NM athletes, estradiol negatively correlated with mean velocity and power (r=-0.44 to -0.50, p<0.047), progesterone positively correlated with contraction time (r=0.45, p=0.045), and both negatively correlated with the rate of force development and impulse (r=-0.45 to -0.64, p<0.043) during the SJ. During the CMJ, estradiol positively correlated to 200ms impulse (r=0.45, p=0.049) and progesterone to mean power (r=0.51, p=0.021). Evidence of changes in testing performance across a MC, or during active HC use, is insufficient to justify "phase-based testing"; however, kinetic or kinematic outputs may be altered in NM athletes.